Roy Galvin's most recent trade in Haemonetics Corp. was a trade of 14,626 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 16, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 14,626 | 14,626 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 6,755 | 13,998 (0%) | 0% | - | Common Stock | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 15 May 2025 | 257 | 7,243 (0%) | 0% | 70.3 | 18,070 | Common Stock |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 15 May 2025 | 201 | 7,500 (0%) | 0% | 69.4 | 13,945 | Common Stock |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.48 per share. | 01 Nov 2024 | 161 | 7,373 (0%) | 0% | 71.5 | 11,508 | Common Stock |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 6,313 | 6,313 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 2,872 | 7,410 (0%) | 0% | - | Common Stock | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.49 per share. | 15 May 2024 | 214 | 4,538 (0%) | 0% | 96.5 | 20,649 | Common Stock |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.39 per share. | 01 Nov 2023 | 160 | 4,595 (0%) | 0% | 86.4 | 13,822 | Common Stock |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 5,068 | 5,068 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 2,243 | 4,689 (0%) | 0% | - | Common Stock | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 5,263 | 5,263 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Roy Galvin | President, Global Plasma & BC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 2,382 | 2,382 (0%) | 0% | - | Common Stock |